Chemomab director reports initial share and option holdings
Chemomab Therapeutics Ltd. director Neil Harris Cohen filed a Form 3 disclosing his initial beneficial ownership in the company’s American Depositary Shares.
Rhea-AI Filing Summary
Chemomab Therapeutics Ltd. director Neil Harris Cohen filed a Form 3 disclosing his initial beneficial ownership in the company’s American Depositary Shares. He directly holds 35,304 American Depositary Shares as of the reporting date.
He also holds several stock options to buy additional American Depositary Shares at exercise prices ranging from $2.14 to $109.04 per share, with expirations between 2030 and 2036. Footnotes state these options were granted between July 16, 2020 and March 16, 2025 and are all fully vested and exercisable as of the report date, showing his existing equity-based compensation position rather than new market transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Cohen Neil Harris
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | Stock option (right to buy American Depositary Shares) | -- | -- | -- |
| holding | American Depositary Shares | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy American Depositary Shares) — 18,075 contracts (Direct);
American Depositary Shares — 35,304 shares (Direct)
Footnotes (6)
- F1. The options reported in this row were granted to the Reporting Person by the Issuer on July 16, 2020, and are fully vested and exercisable as of the date of this report.
- F2. The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.
- F3. The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.
- F4. The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.
- F5. The options reported in this row were granted to the Reporting Person by the Issuer on March 18, 2024, and are fully vested and exercisable as of the date of this report.
- F6. The options reported in this row were granted to the Reporting Person by the Issuer on March 16, 2025, and are fully vested and exercisable as of the date of this report.
Key Figures
Direct ADS holdings: 35,304 American Depositary Shares
Option exercise price: $52.80 per share
Option exercise price: $109.04 per share
+5 more
8 metrics
Direct ADS holdings
35,304 American Depositary Shares
Directly owned as of Form 3 reporting date
Option exercise price
$52.80 per share
Stock option expiring July 16, 2030; 172 underlying ADS
Option exercise price
$109.04 per share
Stock option expiring April 19, 2031; 2,971 underlying ADS
Option exercise price
$14.12 per share
Stock option expiring March 7, 2032; 1,705 underlying ADS
Option exercise price
$6.48 per share
Stock option expiring March 21, 2033; 1,714 underlying ADS
Option exercise price
$2.96 per share
Stock option expiring March 18, 2034; 2,520 underlying ADS
Option exercise price
$6.16 per share
Stock option expiring March 16, 2035; 3,821 underlying ADS
Option exercise price
$2.14 per share
Stock option expiring March 16, 2036; 5,172 underlying ADS
Key Terms
American Depositary Shares, Stock option (right to buy American Depositary Shares), fully vested and exercisable
3 terms
fully vested and exercisable financial
"are fully vested and exercisable as of the date of this report"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider holdings did CMMB director Neil Harris Cohen report on this Form 3?
Neil Harris Cohen reported direct ownership of 35,304 American Depositary Shares of Chemomab Therapeutics Ltd. He also disclosed multiple fully vested stock options giving him the right to buy additional American Depositary Shares at various exercise prices and expiration dates, reflecting his existing equity compensation.
Are Neil Harris Cohen’s Chemomab stock options vested and exercisable?
Yes. Footnotes state each option grant reported is fully vested and exercisable as of the report date. The options were granted on dates from July 16, 2020 through March 16, 2025, so he can choose to exercise them any time before their respective expiration dates.
Does this CMMB Form 3 show any recent insider buying or selling activity?
The Form 3 shows holdings only, not new purchases or sales. Transaction records are categorized as holdings with unknown transaction codes, and summary data show no buy, sell, exercise, gift, or tax-withholding transactions, indicating this filing primarily establishes Neil Harris Cohen’s existing position.
What is the lowest exercise price among Neil Harris Cohen’s Chemomab options?
The lowest disclosed exercise price is $2.14 per American Depositary Share for an option expiring on March 16, 2036, covering 5,172 underlying shares. This grant is fully vested and exercisable according to the footnotes included with the filing.
What is the highest exercise price among the Chemomab options reported?
The highest disclosed exercise price is $109.04 per American Depositary Share, tied to options over 2,971 underlying shares expiring on April 19, 2031. Footnotes state these options were granted on that date and are fully vested and exercisable as of the report date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
